23andMe Holding Co. (NASDAQ:ME - Get Free Report) was the target of unusually large options trading activity on Wednesday. Investors bought 7,134 call options on the company. This represents an increase of 812% compared to the average daily volume of 782 call options.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of 23andMe in a research report on Friday, March 7th.
Get Our Latest Report on 23andMe
23andMe Trading Up 1.7 %
ME traded up $0.03 on Friday, reaching $1.79. The stock had a trading volume of 205,480 shares, compared to its average volume of 264,000. 23andMe has a 12-month low of $1.34 and a 12-month high of $12.76. The business's 50-day moving average price is $2.55 and its two-hundred day moving average price is $3.93. The company has a market cap of $48.02 million, a P/E ratio of -0.12 and a beta of 1.19.
23andMe (NASDAQ:ME - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.
Hedge Funds Weigh In On 23andMe
A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of 23andMe by 0.7% in the third quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company's stock valued at $1,476,000 after acquiring an additional 28,252 shares in the last quarter. Leavell Investment Management Inc. acquired a new stake in shares of 23andMe during the fourth quarter worth about $32,000. FNY Investment Advisers LLC purchased a new stake in 23andMe in the fourth quarter valued at approximately $26,000. MassMutual Private Wealth & Trust FSB acquired a new stake in 23andMe during the 4th quarter worth $40,000. Finally, Shay Capital LLC boosted its stake in shares of 23andMe by 71.7% during the fourth quarter. Shay Capital LLC now owns 702,530 shares of the company's stock worth $2,283,000 after buying an additional 293,358 shares during the period. Hedge funds and other institutional investors own 36.10% of the company's stock.
About 23andMe
(
Get Free Report)
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Featured Articles
Before you consider 23andMe, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 23andMe wasn't on the list.
While 23andMe currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
